Is McKesson (MCK) Outperforming Other Medical Stocks This Year?

McKesson (MCK) is significantly outperforming the broader Medical sector, with a year-to-date return of 26.6% compared to the sector's average loss of 4.9%; this outperformance is supported by a Zacks Rank of #2 (Buy) and a 1.4% increase in full-year earnings estimates over the past quarter. Adagene Inc. Sponsored ADR (ADAG) is also outperforming the sector with a year-to-date return of 4.8% and a 7.9% increase in the consensus EPS estimate for the current year over the past three months, also holding a Zacks Rank #2 (Buy).

Analysis

McKesson (MCK) is demonstrating significant outperformance within the Medical sector, registering a year-to-date return of approximately 26.6%, starkly contrasting with the Medical group's average loss of 4.9%. This robust performance is further substantiated by its Zacks Rank of #2 (Buy) and a 1.4% upward revision in its full-year earnings consensus estimate over the past quarter, signaling improving analyst sentiment and a positive earnings outlook. McKesson also outperforms its specific Medical - Dental Supplies industry, which has seen an average loss of 1.9% year-to-date. The broader Medical sector, despite a Zacks Sector Rank of #4 (out of 16 groups), indicating a relatively strong aggregate earnings outlook for its constituents based on the average Zacks Rank, has underperformed with a 4.9% loss year-to-date. Similarly, Adagene Inc. Sponsored ADR (ADAG) is another notable outperformer in the Medical sector, with a year-to-date return of 4.8%. ADAG also holds a Zacks Rank #2 (Buy), and its consensus EPS estimate for the current year has increased by 7.9% over the past three months. While its Medical - Biomedical and Genetics industry has declined by 2.9% year-to-date, ADAG's positive trajectory and estimate revisions make it stand out. The Zacks Rank system, which emphasizes earnings estimates and revisions and has a documented history of success, suggests these individual stocks with #2 (Buy) ratings may be positioned to outperform the market over the next one to three months.

Key Decisions for Investors

• Investors seeking exposure to the Medical sector could consider McKesson (MCK) given its substantial 26.6% year-to-date outperformance, a 1.4% positive revision in full-year earnings estimates, and its #2 (Buy) Zacks Rank, all indicating potential for continued strength.
• Adagene Inc. (ADAG) also warrants attention due to its 4.8% year-to-date return, a significant 7.9% increase in current year EPS estimates, and a #2 (Buy) Zacks Rank, highlighting its potential to outperform despite broader sector and industry weakness.
• It is advisable to monitor the persistence of positive earnings estimate revisions for both MCK and ADAG, as these are key drivers of their favorable Zacks Ranks and are indicative of ongoing fundamental strength.
• While MCK and ADAG exhibit individual strength, the overall Medical sector's -4.9% year-to-date loss, even with a relatively strong #4 Zacks Sector Rank, suggests a cautious approach to broad sector allocation and reinforces the importance of focusing on fundamentally sound individual companies.